Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Gains from Investment Securities (2021 - 2025)

Silence Therapeutics' Gains from Investment Securities history spans 4 years, with the latest figure at $20.9 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 19.64% year-over-year to $20.9 million; the TTM value through Dec 2025 reached $20.9 million, up 19.64%, while the annual FY2025 figure was $20.9 million, 19.64% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $20.9 million at Silence Therapeutics, up from -$3.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $20.9 million in Q4 2025 and bottomed at -$3.4 million in Q3 2025.
  • The 4-year median for Gains from Investment Securities is $13000.0 (2024), against an average of $4.5 million.
  • The largest annual shift saw Gains from Investment Securities soared 166.13% in 2024 before it tumbled 6812.24% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $3.6 million in 2021, then skyrocketed by 81.27% to $6.6 million in 2023, then skyrocketed by 166.13% to $17.5 million in 2024, then rose by 19.64% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Gains from Investment Securities are $20.9 million (Q4 2025), -$3.4 million (Q3 2025), and $75000.0 (Q2 2025).